CellzDirect provides hepatocyte-based cell products and related services used in the testing of new drugs. The transaction is subject to customary closing conditions and is expected to close in the first quarter. The acquisition is expected to be EPS neutral in fiscal year 2008, becoming accretive in fiscal year 2009.
Greg Lucier, chairman and CEO of Invitrogen, said: “CellzDirect’s high-value products and services will greatly complement Invitrogen’s market-leading portfolio of complete cell systems, including primary cells, media, matrices and growth factors.”